drugset / Trial / NCT04060849
Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY
Phase 1
Terminated
10 enrolled
Fred Hutchinson Cancer Center
Global Life Technologies Corp. · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
This phase I trial studies the side effects of Nozin in preventing respiratory viral infections in patients undergoing stem cell transplant. Nozin is a non-antibiotic, alcohol-based nasal sanitizer used in hospitals to prevent spread of bacterial infections and may also prevent community acquired respiratory virus infection in stem cell transplant recipients.
Timeline
- Start
- 2019-09-03
- Primary completion
- 2020-04-12
- Completion
- 2020-04-12
Outcome
Outcome not reported
Stopped (Enrollment): “The study was closed to accrual according to the Fred Hutch/University of Washington/Seattle Children's Consortium low accrual institutional policy.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nozin | Unknown | — | Intranasal |